Is DNLI a buy or sell?
Denali Therapeutics (DNLI) currently holds a "Strong Buy" consensus rating among investment analysts. Recent market data indicates that out of 16 analysts providing coverage, 19 recommend buying the stock, while zero suggest selling, and one recommends holding a position. This high level of confidence is driven by the company's progress in its clinical pipeline and its strategic transition toward becoming a commercial-stage biotech firm. While this rating reflects professional sentiment, investors should always consider the inherent volatility of the biotechnology sector and perform their own due diligence to ensure the stock aligns with their specific risk tolerance and financial goals before making a decision.
Related FAQs
Yes, Dentsu offers a hybrid work model that incorporates remote work.
Huizhou Desay SV Automotive Co., Ltd.
Transforming an older, non-smart television into a modern smart TV is an easy and cost-effective process that involves connecting an external streaming media device to one of the TV's HDMI ports.
Employees working at Axalta Coating Systems—a leading global provider of liquid and powder coatings—earn professional salaries that vary significantly based on chemical engineering expertise, manufacturing plant operations, and technical research ...
Denali Therapeutics (DNLI) currently holds a consensus analyst rating of "Buy," with a majority of analysts suggesting it is a strong prospect.
Whether Denali Therapeutics is a "good" stock depends on your appetite for risk.
Yes, Denali Therapeutics (DNLI) received FDA approval in 2026 for AVLAYAH, which is the company's first commercial drug designed to treat pediatric Hunter syndrome.